CNXU.US Conexeu Sciences Inc. Common Stock
- Market cap
- USD 67.2M
- P/E
- -
- P/B
- 11.49x
- ROE
- -267.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jul 2026.
Is CNXU.US undervalued?
Graham numberThe Graham number of Conexeu Sciences Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Conexeu Sciences Inc. Common Stock fundamental analysis
No fundamental analysis for Conexeu Sciences Inc. Common Stock yet.
Conexeu Sciences Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational p…
Full company profileConexeu Sciences Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jul 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Conexeu Sciences Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | -643K | -3.96M | -15.7M |
| EBITDA | -455K | -3.90M | -15.6M |
| Net Income | -472K | -3.92M | -15.7M |
| EPS | -0.02 | -0.19 | -0.57 |
| Balance Sheet | |||
| Total Assets | 534K | 7.69M | 7.16M |
| Total Liabilities | 439K | 336K | 1.31M |
| Shareholders' Equity | 95.0K | 7.35M | 5.85M |
| Cash & Short-term Investments | 315K | 4.81M | 1.97M |
| Cash Flow | |||
| Operating Cash Flow | -225K | -1.67M | -13.5M |
| Capital Expenditure | 0.00 | 18.7K | 102K |
| Free Cash Flow | -225K | -1.69M | -13.6M |
| Ratios | |||
| ROE | -496.9% | -53.4% | -267.8% |
| ROA | -88.4% | -51.0% | -218.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Conexeu Sciences Inc. Common Stock dividends
Conexeu Sciences Inc. Common Stock has not paid dividends in the last 2 fiscal years.
Who owns Conexeu Sciences Inc. Common Stock
- Insiders 47.77%
- Institutions 9.11%
- Public & others 43.12%
- Shares outstanding 30.8M
- Free float 16.5M
Top funds holding CNXU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 92.3K | 0.30% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 69.4K | 0.23% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 24.9K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 23.1K | 0.07% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 6.73K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding CNXU.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| UBS Group AG | 12.3K | 0.04% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.87K | 0.02% | 0.00% | Jun 2026 |
| Citigroup Inc | 5.22K | 0.02% | 0.00% | Jun 2026 |
| Hollencrest Securities, LLC | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 887.00 | 0.00% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 425.00 | 0.00% | 0.00% | Jun 2026 |
| Integrated Wealth Concepts LLC | 400.00 | 0.00% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 100.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 100.00 | 0.00% | 0.00% | Jun 2026 |
Conexeu Sciences Inc. Common Stock company profile
- Company name
- Conexeu Sciences Inc. Common Stock
- Ticker
- CNXU.US
- Exchange
- USA Stocks
- Listed since
- May 21, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- October
- Address
- 50 West Liberty Street, Reno, NV, United States, 89501
- Phone
- (604) 315-4722
- Website
- conexeu.com
About Conexeu Sciences Inc. Common Stock
Conexeu Sciences Inc. develops collagen-based regenerative tissue scaffold products for applications in medical aesthetics and tissue repair. The company provides patented collagen-based scaffold products, including a collagen extracellular matrix (ECM) scaffold platform for use in medical aesthetics, wound care, tissue repair, facial rejuvenation, and large-volume body contouring such as face, breast, and butt volume restoration. Its CXU collagen gel is an investigational product targeting therapeutic and aesthetic indications, supporting tissue regeneration and aiming to minimize inflammation or fibrosis. The company's solutions are supported by preclinical and peer-reviewed data and are positioned as alternatives to conventional fillers or implants, with products currently investigational and pending regulatory clearance for certain applications. The company serves clients in the beauty, aesthetics, regenerative medicine, and medical sectors, including clinicians and professionals involved in facial rejuvenation, body contouring, wound care, and tissue repair. The company was founded in 2022 and is based in Reno, Nevada.
Conexeu Sciences Inc. Common Stock management
7- Mr. Miles D. HarrisonPresident, CEO & Director · born 1965
- Mr. David R. BogartFounder, Chief Commercial Officer & Director · born 1970
- Dr. Claudia Chavez-Munoz M.D., Ph.D.Founder & Chief Scientific Officer · born 1980
- Mr. Stephen D. InouyeCFO, Corporate Secretary & Treasurer · born 1961
- Dr. Brian K. Pilcher Ph.D.Chief Medical Officer · born 1969
- Ms. Sonia Thomas M.B.A.Head of Strategy & Transformation
- Mr. Jean-Romain FalconneHead of Business Development & Licensing